Literature DB >> 8561842

Anticonvulsant and other non-neuroleptic treatment of agitation in dementia.

P N Tariot1, L S Schneider, I R Katz.   

Abstract

Studies have shown that the vast majority of patients with dementia experience some psychopathologic symptoms during the course of their illness. Symptoms of this nature, which can include frightening hallucinations or anxiety of phobic proportions, are subjectively distressing and can lead both to unsafe or violent situations as well as to the preventable use of inappropriate medication, physical restraint, and frequently to institutionalization. These psychopathologic manifestations of dementia often prove to be a burden on family, caregivers, and the health care system as well. This article presents an overview of the assessment and management of agitation as it relates to the severity of dementia symptoms and cognitive deterioration. Specifically, the use of anticonvulsant and other non-neuroleptic therapies is examined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8561842     DOI: 10.1177/089198879500800105

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  9 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence.

Authors:  Yunie Kim; Kirsten M Wilkins; Rajesh R Tampi
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients.

Authors:  H J Kopecky; C R Kopecky; S C Yudofsky
Journal:  Psychiatr Q       Date:  1998

5.  The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.

Authors:  Kate de Medeiros; P Robert; S Gauthier; F Stella; A Politis; J Leoutsakos; F Taragano; J Kremer; A Brugnolo; A P Porsteinsson; Y E Geda; H Brodaty; G Gazdag; J Cummings; C Lyketsos
Journal:  Int Psychogeriatr       Date:  2010-07-01       Impact factor: 3.878

Review 6.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

7.  Neuroprotective properties of valproate: potential benefit for AD and tauopathies.

Authors:  Rebekah Loy; Pierre N Tariot
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

8.  Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011-2014.

Authors:  Lauren B Gerlach; Helen C Kales; Hyungjin Myra Kim; Julie P W Bynum; Claire Chiang; Julie Strominger; Donovan T Maust
Journal:  J Am Med Dir Assoc       Date:  2020-07-18       Impact factor: 4.669

9.  Gabapentin in the treatment of dementia-associated nocturnal agitation.

Authors:  Jitka Buskova; Petr Busek; Sona Nevsimalova
Journal:  Med Sci Monit       Date:  2011-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.